Improved data quality and analysis results through greater biotin incorporation with the Single Round RNA Amplification and Biotin Labeling System for transcriptional analysis

Biotin-labeled antisense RNA (aRNA) is generated from total cellular RNA samples in less than 24 hours. Incorporation of two biotin nucleotides yields brighter signal, improving data from microarray experiments.

• Convenient workflow with a flexible 4-16 hour transcription time and reagents supplied in a ready-to-use format.
• Decrease experimental variation, and standardize data derived from microarrays.
• Maintain the value of legacy data by the continued use of the gold standard for GeneChip® visualization.
• Enables correlation of results from experiment-to-experiment, project-to-project and lab-to-lab.
• Production of large amounts of biotin-labeled RNA targets by in vitro transcription from bacteriophage T7 RNA polymerase promoters is available separately with our BioArray HighYield® RNA Transcript Labeling Kits.

Analyze limiting quantities of total RNA with the BIOARRAY™ Low Input RNA Amplification and Biotin Labeling System for transcript analysis

• Generates sufficient aRNA for standard microarray analysis from as little as 20 ng of total input RNA.
• Entire amplification reaction can be performed in a single tube.
• Superior 3’/5’ transcript ratios demonstrating efficient in vitro transcription.
• Biotin-labeled aRNA can be purified using either magnetic beads or purification columns and reagents

BIOARRAY™ 3´-OH Terminal Labeling is the recognized benchmark standard for biotin-labeling of DNA

The kit is considered the gold standard end-labeling system for use with Affymetrix® DNA SNP (single nucleotide polymorphism), resequencing and prokaryotic microarrays. This method uses Bio-ddUTP and terminal deoxynucleotide transferase to catalyze the addition of a single biotin-ddUMP (2’,3’-dideoxyuridine 5’-monophosphate) to the 3’-OH terminus of an amplified and fragmented target DNA molecule.

References:

1. Akiyama, M et.al. Analysis of telomerase activity and RNA expression in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid. Pediatric Blood & Cancer. Volume 46, Issue 4, 2006, 506-511.